Point72 Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Point72 Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.06M	Sell	461,856 -3,406,826	-88%	-$15.8M	﹤0.01%	2283
2025 Q4	$21.3M	Sell	3,868,682 -3,462,788	-47%	-$16.8M	0.02%	846
2025 Q3	$24M	Buy	7,331,470 +13,856	+0.2%	+$39.2K	0.04%	494
2025 Q2	$16.9M	Buy	7,317,614 +2,747,936	+60%	+$5.97M	0.03%	561
2025 Q1	$6.35M	Buy	+4,569,678	New	+$7.64M	0.01%	843
2024 Q2	–	Sell	-1,113,232	Closed	-$3.19M	–	2455
2024 Q1	$3.19M	Sell	1,113,232 -1,574,768	-59%	-$3.28M	0.01%	1112
2023 Q4	$4.76M	Buy	2,688,000 +1,751,450	+187%	+$3.49M	0.01%	946
2023 Q3	$2.96M	Buy	+936,550	New	+$1.75M	0.01%	1036
2021 Q1	–	Sell	-13,366	Closed	-$355K	–	1183
2020 Q4	$355K	Sell	13,366 -186,634	-93%	-$4.02M	﹤0.01%	856
2020 Q3	$4.48M	Buy	+200,000	New	+$4.7M	0.02%	585

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management's TSHA Position: Q1 2026 in Review

Point72 Asset Management reduced its Taysha Gene Therapies (TSHA) stake by 88% in Q1 2026, selling an estimated $15.8M and leaving 461,856 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Point72 Asset Management first reported a position in TSHA in Q3 2020 and has held it in 10 quarters since. The position peaked at $24M in Q3 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Point72 Asset Management held 461,856 shares of Taysha Gene Therapies worth $2.06M as of Q1 2026.
Point72 Asset Management sold 3,406,826 Taysha Gene Therapies shares in Q1 2026, an estimated $15.8M.
Taysha Gene Therapies made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2283 holding.
Point72 Asset Management first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 10 quarters since.
Point72 Asset Management's Taysha Gene Therapies position peaked at $24M in Q3 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.